1. McMurray, JJ, Packer, M, Desai, AS, et al.; Investigators P-H, Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
Google Scholar | Crossref | Medline | ISI2. Rhea, IB, Oliveira, GH. Cardiotoxicity of novel targeted chemotherapeutic agents. Curr Treat Options Cardiovasc Med. 2018;20:53.
Google Scholar | Crossref | Medline3. Menna, P, Paz, OG, Chello, M, Covino, E, Salvatorelli, E, Minotti, G. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11:S21-S36.
Google Scholar | Crossref | Medline4. Lynce, F, Barac, A, Geng, X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175:595-603.
Google Scholar | Crossref | Medline5. Jordan, JH, Vasu, S, Morgan, TM, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging. 2016;9:e004325.
Google Scholar | Crossref | Medline6. Ferreira de Souza, T, Quinaglia, ACST, Osorio Costa, F, et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging. 2018;11:1045-1055.
Google Scholar | Crossref | Medline7. Li, X, Li, Y, Zhang, T, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res. 2020;151:104577.
Google Scholar | Crossref8. Wachter, R, Senni, M, Belohlavek, J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998-1007.
Google Scholar | Crossref | Medline9. Velazquez, EJ, Morrow, DA, DeVore, AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539-548.
Google Scholar | Crossref | Medline10. Na, SY, Sung, JY, Chang, JH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol. 2011;33:121-130.
Google Scholar | Crossref | Medline | ISI11. Sheppard, CE, Anwar, M. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: a mini case series. J Oncol Pharm Pract. 2019;25:1231-1234.
Google Scholar | SAGE Journals | ISI12. Martin-Garcia, A, Diaz-Pelaez, E, Martin-Garcia, AC, Sanchez-Gonzalez, J, Ibanez, B, Sanchez, PL. Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2020;73:268-269.
Google Scholar | Medline13. Mulay, S, Boruchov, A. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab. Leuk Lymphoma. 2015;56:805-807.
Google Scholar | Crossref | Medline14. Kanamori, H, Tsutsumi, Y, Mori, A, et al. Delayed reduction in left ventricular function following treatment of non-Hodgkin’s lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction. Cardiology. 2006;105:184-187.
Google Scholar | Crossref | Medline15. Januzzi, JL, Prescott, MF, Butler, J, et al.; Investigators P-H. Association of change in N-Terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1-11.
Google Scholar | Crossref16. Lee, YH, Chiou, WR, Hsu, CY, et al. Different left ventricular remodeling patterns and clinical outcomes between non-ischemic and ischemic etiologies in heart failure patients receiving sacubitril/valsartan treatment. Eur Heart J Cardiovasc Pharmacother. Published online October 29, 2020. doi:10.1093/ehjcvp/pvaa125
Google Scholar | Crossref17. Bayard, G, Da Costa, A, Pierrard, R, Romeyer-Bouchard, C, Guichard, JB, Isaaz, K. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasc. 2019;25:100418.
Google Scholar | Medline18. Landolfo, M, Piani, F, Esposti, DD, et al. Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction. Int J Cardiol Heart Vasc. 2020;31:100656.
Google Scholar | Medline19. Martin-Garcia, A, Lopez-Fernandez, T, Mitroi, C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020;7:763-767.
Google Scholar | Crossref | Medline20. De Vecchis, R, Paccone, A. A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. SAGE Open Med Case Rep. 2020;8:2050313X20952189.
Google Scholar | Medline